Literature DB >> 23708667

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.

Y Cai1, E-J Geutjes2, K de Lint2, P Roepman3, L Bruurs2, L-R Yu4, W Wang1, J van Blijswijk2, H Mohammad1, I de Rink5, R Bernards2, S B Baylin1.   

Abstract

Many tumor suppressor genes (TSGs) are silenced through synergistic layers of epigenetic regulation including abnormal DNA hypermethylation of promoter CpG islands, repressive chromatin modifications and enhanced nucleosome deposition over transcription start sites. The protein complexes responsible for silencing of many of such TSGs remain to be identified. Our previous work demonstrated that multiple silenced TSGs in colorectal cancer cells can be partially reactivated by DNA demethylation in cells disrupted for the DNA methyltransferases 1 and 3B (DNMT1 and 3B) or by DNMT inhibitors (DNMTi). Herein, we used proteomic and functional genetic approaches to identify additional proteins that cooperate with DNMTs in silencing these key silenced TSGs in colon cancer cells. We discovered that DNMTs and the core components of the NuRD (Mi-2/nucleosome remodeling and deacetylase) nucleosome remodeling complex, chromo domain helicase DNA-binding protein 4 (CHD4) and histone deacetylase 1 (HDAC1) occupy the promoters of several of these hypermethylated TSGs and physically and functionally interact to maintain their silencing. Consistent with this, we find an inverse relationship between expression of HDAC1 and 2 and these TSGs in a large panel of primary colorectal tumors. We demonstrate that DNMTs and NuRD cooperate to maintain the silencing of several negative regulators of the WNT and other signaling pathways. We find that depletion of CHD4 is synergistic with DNMT inhibition in reducing the viability of colon cancer cells in correlation with reactivation of TSGs, suggesting that their combined inhibition may be beneficial for the treatment of colon cancer. Since CHD4 has ATPase activity, our data identify CHD4 as a potentially novel drug target in cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708667      PMCID: PMC3883927          DOI: 10.1038/onc.2013.178

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation.

Authors:  Y Zhang; H H Ng; H Erdjument-Bromage; P Tempst; A Bird; D Reinberg
Journal:  Genes Dev       Date:  1999-08-01       Impact factor: 11.361

Review 2.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

3.  Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication.

Authors:  Pierre-Olivier Estève; Hang Gyeong Chin; Andrea Smallwood; George R Feehery; Omkaram Gangisetty; Adam R Karpf; Michael F Carey; Sriharsa Pradhan
Journal:  Genes Dev       Date:  2006-11-03       Impact factor: 11.361

4.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.

Authors:  X Nan; H H Ng; C A Johnson; C D Laherty; B M Turner; R N Eisenman; A Bird
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

5.  The Polycomb group protein EZH2 directly controls DNA methylation.

Authors:  Emmanuelle Viré; Carmen Brenner; Rachel Deplus; Loïc Blanchon; Mario Fraga; Céline Didelot; Lluis Morey; Aleyde Van Eynde; David Bernard; Jean-Marie Vanderwinden; Mathieu Bollen; Manel Esteller; Luciano Di Croce; Yvan de Launoit; François Fuks
Journal:  Nature       Date:  2005-12-14       Impact factor: 49.962

6.  Modulation of DNMT1 activity by ADP-ribose polymers.

Authors:  Anna Reale; Giovanna De Matteis; Giada Galleazzi; Michele Zampieri; Paola Caiafa
Journal:  Oncogene       Date:  2005-01-06       Impact factor: 9.867

7.  Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation.

Authors:  P A Wade; A Gegonne; P L Jones; E Ballestar; F Aubry; A P Wolffe
Journal:  Nat Genet       Date:  1999-09       Impact factor: 38.330

8.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer.

Authors:  Hiromu Suzuki; D Neil Watkins; Kam-Wing Jair; Kornel E Schuebel; Sanford D Markowitz; Wei Dong Chen; Theresa P Pretlow; Bin Yang; Yoshimitsu Akiyama; Manon Van Engeland; Minoru Toyota; Takashi Tokino; Yuji Hinoda; Kohzoh Imai; James G Herman; Stephen B Baylin
Journal:  Nat Genet       Date:  2004-03-14       Impact factor: 38.330

9.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.

Authors:  E E Cameron; K E Bachman; S Myöhänen; J G Herman; S B Baylin
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

10.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

Authors:  R Jüttermann; E Li; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

View more
  47 in total

Review 1.  Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

Authors:  A Prahallad; R Bernards
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

2.  Expression of the dermatomyositis autoantigen transcription intermediary factor 1γ in regenerating muscle.

Authors:  Payam Mohassel; Paul Rosen; Livia Casciola-Rosen; Katherine Pak; Andrew L Mammen
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

3.  Deep proteomic analysis of Dnmt1 mutant/hypomorphic colorectal cancer cells reveals dysregulation of epithelial-mesenchymal transition and subcellular re-localization of Beta-Catenin.

Authors:  Emily H Bowler; Alex Smith-Vidal; Alex Lester; Joseph Bell; Zhenghe Wang; Christopher G Bell; Yihua Wang; Nullin Divecha; Paul J Skipp; Rob M Ewing
Journal:  Epigenetics       Date:  2019-08-26       Impact factor: 4.528

Review 4.  The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.

Authors:  Alea A Mills
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

5.  CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes.

Authors:  Limin Xia; Wenjie Huang; Marina Bellani; Michael M Seidman; Kaichun Wu; Daiming Fan; Yongzhan Nie; Yi Cai; Yang W Zhang; Li-Rong Yu; Huili Li; Cynthia A Zahnow; Wenbing Xie; Ray-Whay Chiu Yen; Feyruz V Rassool; Stephen B Baylin
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

Review 6.  Reprogramming: identifying the mechanisms that safeguard cell identity.

Authors:  Justin Brumbaugh; Bruno Di Stefano; Konrad Hochedlinger
Journal:  Development       Date:  2019-12-02       Impact factor: 6.868

Review 7.  Harnessing the potential of epigenetic therapy to target solid tumors.

Authors:  Nita Ahuja; Hariharan Easwaran; Stephen B Baylin
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 8.  Epigenetic Determinants of Cancer.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

Review 9.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

10.  Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B.

Authors:  X-D Li; J-X Zhang; L-J Jiang; F-W Wang; L-L Liu; Y-J Liao; X-H Jin; W-H Chen; X Chen; S-J Guo; F-J Zhou; Y-X Zeng; X-Y Guan; Z-W Liu; D Xie
Journal:  Oncogene       Date:  2016-05-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.